Kdr (kinase insert domain receptor) - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Kdr (kinase insert domain receptor) Rattus norvegicus
Analyze
Symbol: Kdr
Name: kinase insert domain receptor
RGD ID: 2965
Description: Enables growth factor binding activity and vascular endothelial growth factor receptor activity. Involved in several processes, including positive regulation of endothelial cell proliferation; positive regulation of intracellular signal transduction; and positive regulation of long-term neuronal synaptic plasticity. Located in several cellular components, including neuron projection; neuronal cell body; and plasma membrane. Used to study adhesions of uterus; brain ischemia; cystitis; and myocardial infarction. Biomarker of several diseases, including artery disease (multiple); impotence; ovarian hyperstimulation syndrome; prostate disease (multiple); and retinopathy of prematurity. Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); breast angiosarcoma; gastrointestinal system cancer (multiple); macular degeneration (multiple); and pancreatic cancer (multiple). Orthologous to human KDR (kinase insert domain receptor); PARTICIPATES IN altered vascular endothelial growth factor signaling pathway involving proteins affecting its expression; altered vascular endothelial growth factor signaling pathway involving the main players; vascular endothelial growth factor signaling pathway; INTERACTS WITH (S)-nicotine; 1,2,4-trimethylbenzene; 17alpha-ethynylestradiol.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: fetal liver kinase 1; FLK-1; FLK1 kinase insert domain receptor (a type III receptor tyrosine kinase) (VEGF receptor 2); FLK1 kinase insert domain receptor (VEGF receptor 2); kinase insert domain protein receptor; MGC93590; protein-tyrosine kinase receptor flk-1; vascular endothelial growth factor receptor 2; Vegfr-2
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.21432,217,871 - 32,261,018 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1432,217,871 - 32,261,018 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1432,577,934 - 32,621,098 (+)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.01433,885,873 - 33,929,041 (+)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.01432,370,973 - 32,414,143 (+)NCBIRnor_WKY
Rnor_6.01434,727,677 - 34,787,127 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1434,727,623 - 34,787,183 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01434,557,361 - 34,618,112 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera1431,512,534 - 31,554,989 (+)NCBICelera
Cytogenetic Map14p11NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
Acute Lung Injury  (IEP)
adenocarcinoma  (ISO)
adhesions of uterus  (IMP,ISO)
allergic contact dermatitis  (ISO)
amyotrophic lateral sclerosis  (ISO)
angiosarcoma  (ISO)
Animal Mammary Neoplasms  (ISO)
arteriosclerosis  (IEP,ISO)
arteriovenous malformations of the brain  (ISO)
asthma  (ISO)
atherosclerosis  (ISO)
brain glioma  (ISO)
Brain Hypoxia-Ischemia  (IMP)
Brain Injuries  (IEP,IMP)
brain ischemia  (IMP)
breast angiosarcoma  (ISO)
breast cancer  (ISO)
breast carcinoma  (ISO)
Breast Neoplasms  (ISO)
cerebral cavernous malformation  (ISO)
Cerebral Hemorrhage  (ISO)
Choroidal Neovascularization  (IDA,IMP,ISO)
chronic obstructive pulmonary disease  (ISO)
colitis  (IEP)
colon carcinoma  (ISO)
Colonic Neoplasms  (ISO)
colorectal adenocarcinoma  (ISO)
colorectal cancer  (ISO)
Colorectal Neoplasms  (ISO)
contact dermatitis  (ISO)
corneal neovascularization  (ISO)
Coronary Disease  (ISO)
Crohn's disease  (ISO)
cystitis  (IDA)
decubitus ulcer  (ISO)
Diabetic Nephropathies  (ISO)
diffuse scleroderma  (ISO)
Endometrial Neoplasms  (ISO)
Endometrioid Carcinomas  (ISO)
endometriosis  (IEP)
Esophageal Neoplasms  (ISO)
esophagus adenocarcinoma  (ISO)
Experimental Autoimmune Encephalomyelitis  (ISO)
Experimental Colitis  (ISO)
Experimental Diabetes Mellitus  (IEP,ISO)
Experimental Liver Neoplasms  (ISO)
Experimental Mammary Neoplasms  (IDA,ISO)
glioblastoma  (ISO)
Hand-Foot Syndrome  (ISO)
hemangiopericytoma  (ISO)
hepatoblastoma  (ISO)
hepatocellular carcinoma  (ISO)
herpes simplex virus keratitis  (ISO)
high grade glioma  (ISO)
High Myopia  (ISO)
Hirschsprung's disease  (ISO)
hydrophthalmos  (ISO)
hypertension  (IEP,ISO)
impotence  (IEP)
Infantile Capillary Hemangioma  (ISO)
inverted papilloma  (ISO)
Kidney Neoplasms  (ISO)
Kuhnt-Junius degeneration  (ISO)
Lathyrism  (IEP)
limited scleroderma  (ISO)
liver cirrhosis  (ISO)
lung carcinoma  (ISO)
lung non-small cell carcinoma  (ISO)
lymphangioma  (ISO)
Lymphatic Metastasis  (ISO)
macular degeneration  (ISO)
macular retinal edema  (ISO)
melanoma  (ISO)
myocardial infarction  (IDA,ISO)
Myocardial Ischemia  (ISO)
Nasal Polyps  (ISO)
nasopharynx carcinoma  (ISO)
Neoplasm Metastasis  (ISO)
Neovascularization, Pathologic  (ISO)
Neuralgia  (IEP)
neurilemmoma  (ISO)
neurofibrosarcoma  (ISO)
osteochondrodysplasia  (ISO)
Otitis Media with Effusion  (IEP)
ovarian hyperstimulation syndrome  (IEP)
Ovarian Neoplasms  (ISO)
Oxygen-Induced Retinopathy  (IEP,IMP)
pancreatic cancer  (ISO)
pancreatic carcinoma  (ISO)
primary ovarian insufficiency  (ISO)
prostate adenocarcinoma  (IEP,ISO)
prostate cancer  (ISO)
prostatic hypertrophy  (IEP)
psoriasis  (ISO)
pterygium  (ISO)
renal cell carcinoma  (ISO)
Reperfusion Injury  (IEP,ISO)
retinal telangiectasia  (ISO)
retinopathy of prematurity  (IEP,ISO)
salivary gland carcinoma  (ISO)
sarcoma  (ISO)
schizophrenia  (ISO)
Seasonal Allergic Rhinitis  (ISO)
Spinal Cord Injuries  (IEP)
squamous cell carcinoma  (ISO)
stomach cancer  (ISO)
Stroke  (IMP)
systemic scleroderma  (ISO)
temporal lobe epilepsy  (ISO)
thyroid gland carcinoma  (ISO)
tongue squamous cell carcinoma  (ISO)
transitional cell carcinoma  (ISO)
Transplant Rejection  (ISO)
Tufted Angioma  (ISO)
type 2 diabetes mellitus  (ISO)
ulcerative colitis  (ISO)
uremia  (ISO)
urinary bladder cancer  (ISO)
Uterine Cervical Neoplasms  (ISO)
uveal melanoma  (ISO)
Venous Thrombosis  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(-)-epigallocatechin 3-gallate  (ISO)
(S)-nicotine  (EXP)
1,1-dichloroethene  (ISO)
1,2,4-trimethylbenzene  (EXP)
1,2-dimethylhydrazine  (ISO)
1,4-benzoquinone  (ISO)
17alpha-ethynylestradiol  (EXP)
17beta-estradiol  (EXP,ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (ISO)
2,2',5,5'-tetrachlorobiphenyl  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,3,7,8-Tetrachlorodibenzofuran  (EXP)
2,3-Bis(3-hydroxybenzyl)butane-1,4-diol  (ISO)
2,4-dinitrotoluene  (EXP)
2,6-dinitrotoluene  (EXP)
3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine  (EXP)
3,3',5,5'-tetraiodothyroacetic acid  (ISO)
3,3'-diindolylmethane  (ISO)
3,5,6-trichloro-2-pyridinol  (ISO)
3,5,6-trichloropyridine-2-one  (ISO)
3-\{1-[3-(dimethylamino)propyl]-1H-indol-3-yl\}-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione  (ISO)
3-methylcholanthrene  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-hydroxyphenyl retinamide  (ISO)
5-azacytidine  (EXP)
5-fluorouracil  (ISO)
5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole  (EXP,ISO)
6-propyl-2-thiouracil  (EXP)
afimoxifene  (ISO)
aflatoxin B1  (ISO)
aldehydo-D-glucose  (ISO)
all-trans-retinoic acid  (ISO)
amiodarone  (EXP)
andrographolide  (ISO)
apigenin  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
aspartame  (ISO)
Auriculasin  (ISO)
belinostat  (ISO)
benzbromarone  (EXP)
benzo[a]pyrene  (ISO)
benzylpenicillin  (ISO)
bis(2-chloroethyl) sulfide  (ISO)
bisphenol A  (EXP,ISO)
Bisphenol A diglycidyl ether  (ISO)
bisphenol F  (ISO)
bortezomib  (ISO)
cadmium atom  (ISO)
calcidiol  (EXP)
calcitriol  (EXP)
calcium atom  (ISO)
calcium silicate  (ISO)
calcium(0)  (ISO)
carbon nanotube  (ISO)
chlorpyrifos  (ISO)
choline  (ISO)
clofibrate  (EXP,ISO)
clofibric acid  (EXP)
clozapine  (ISO)
cobalt dichloride  (ISO)
copper atom  (EXP)
copper(0)  (EXP)
corticosterone  (ISO)
coumarin  (ISO)
crocidolite asbestos  (ISO)
curcumin  (EXP,ISO)
Curcumol  (EXP,ISO)
cyclophosphamide  (EXP)
cyclosporin A  (EXP,ISO)
cypermethrin  (ISO)
D-glucose  (ISO)
deguelin  (ISO)
demethoxycurcumin  (ISO)
desferrioxamine B  (ISO)
diarsenic trioxide  (ISO)
diethylstilbestrol  (EXP)
dioscin  (ISO)
dioxygen  (EXP,ISO)
dorsomorphin  (ISO)
doxorubicin  (ISO)
embelin  (ISO)
enalapril  (EXP)
Enterolactone  (ISO)
entinostat  (ISO)
ethanol  (ISO)
ethyl trans-caffeate  (ISO)
flutamide  (EXP)
folic acid  (ISO)
fructose  (EXP)
fumonisin B1  (ISO)
furosemide  (EXP)
galaxolide  (ISO)
gefitinib  (ISO)
genistein  (EXP,ISO)
gentamycin  (EXP)
geraniol  (ISO)
glafenine  (EXP)
glucose  (ISO)
glycidol  (EXP)
glyphosate  (ISO)
haloperidol  (ISO)
hexachlorobenzene  (ISO)
indoles  (EXP)
isoprenaline  (ISO)
L-ascorbic acid  (ISO)
L-ethionine  (EXP)
L-methionine  (ISO)
lead diacetate  (ISO)
lithium chloride  (ISO)
losartan  (EXP)
medroxyprogesterone acetate  (ISO)
melatonin  (ISO)
melittin  (ISO)
methoxychlor  (EXP)
methyl caffeate  (ISO)
methylisothiazolinone  (ISO)
methylmercury chloride  (ISO)
mifepristone  (ISO)
monocrotaline  (ISO)
monosodium L-glutamate  (EXP)
Morroniside  (EXP)
N-acetyl-L-cysteine  (ISO)
N-acetylsphingosine  (ISO)
N-ethyl-N-nitrosourea  (ISO)
N-nitrosodiethylamine  (EXP)
nickel atom  (ISO)
nicotine  (EXP)
nicotinic acid  (ISO)
O-methyleugenol  (ISO)
omeprazole  (EXP,ISO)
orantinib  (ISO)
orlistat  (ISO)
oxaliplatin  (EXP)
ozone  (EXP,ISO)
p-menthan-3-ol  (ISO)
panobinostat  (ISO)
paracetamol  (EXP,ISO)
PCB138  (ISO)
PD123319  (EXP)
perfluorononanoic acid  (ISO)
perfluorooctane-1-sulfonic acid  (EXP,ISO)
perfluorooctanoic acid  (EXP)
phenylephrine  (EXP)
phenytoin  (ISO)
phosgene  (EXP,ISO)
pirinixic acid  (EXP,ISO)
platycodin D  (ISO)
ponatinib  (ISO)
Ponicidin  (ISO)
potassium dichromate  (ISO)
progesterone  (EXP,ISO)
quercetin  (ISO)
quercitrin  (ISO)
quinazolines  (ISO)
resveratrol  (ISO)
riddelliine  (EXP)
rosuvastatin calcium  (ISO)
rotenone  (EXP)
saccharin  (ISO)
sarpogrelate  (ISO)
SB 431542  (ISO)
silicon dioxide  (ISO)
simvastatin  (EXP,ISO)
sodium arsenite  (ISO)
sorafenib  (ISO)
sphingosine 1-phosphate  (ISO)
streptozocin  (EXP,ISO)
sunitinib  (ISO)
superoxide  (ISO)
tanespimycin  (EXP,ISO)
testosterone  (ISO)
tetrachloromethane  (EXP,ISO)
thalidomide  (ISO)
thioacetamide  (EXP)
titanium dioxide  (ISO)
toluene  (EXP)
topotecan  (EXP)
trichloroethene  (EXP,ISO)
triclosan  (ISO)
triptonide  (ISO)
troglitazone  (ISO)
trovafloxacin  (ISO)
tunicamycin  (ISO)
undecane  (EXP)
urea  (ISO)
urethane  (ISO)
valproic acid  (ISO)
valsartan  (EXP,ISO)
vinclozolin  (EXP)
vorinostat  (ISO)
WIN 55212-2  (ISO)
zinc atom  (EXP)
zinc sulfate  (EXP)
zinc(0)  (EXP)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
aging  (IEP)
angiogenesis  (IBA,IEA)
animal organ development  (IEA)
blood vessel endothelial cell differentiation  (IEA,ISO)
branching involved in blood vessel morphogenesis  (IEA,ISO)
branching morphogenesis of an epithelial tube  (ISO)
calcium ion homeostasis  (IEA,ISO)
calcium-mediated signaling using intracellular calcium source  (IEA,ISO,ISS)
cell fate commitment  (IEA,ISO)
cell maturation  (ISO)
cell migration  (IBA,ISO)
cell migration involved in sprouting angiogenesis  (IEA,ISO)
cellular response to hydrogen sulfide  (IEA,ISO)
cellular response to vascular endothelial growth factor stimulus  (ISO,ISS)
embryonic hemopoiesis  (IEA,ISO,ISS)
endocardium development  (IEA,ISO)
endochondral bone growth  (IMP)
endothelial cell differentiation  (IBA,ISO)
endothelial tube morphogenesis  (IMP)
endothelium development  (ISO,ISS)
epithelial cell maturation  (IEA,ISO)
epithelial cell proliferation  (IEA,ISO)
ERK1 and ERK2 cascade  (IEA,ISO)
hematopoietic progenitor cell differentiation  (IBA)
hemopoiesis  (ISO)
lung alveolus development  (IEA,ISO)
lung development  (ISO)
lymph vessel development  (IEA,ISO)
male gonad development  (IDA)
mesenchymal cell proliferation  (IEA,ISO)
negative regulation of apoptotic process  (ISO,ISS)
negative regulation of endothelial cell apoptotic process  (IEA,ISO,ISS)
negative regulation of gene expression  (IEA,ISO)
negative regulation of neuron apoptotic process  (IEA,IMP,ISO)
negative regulation of systemic arterial blood pressure  (IGI)
neuron projection morphogenesis  (IMP)
ovarian follicle development  (IEA,ISO)
peptidyl-tyrosine autophosphorylation  (IEA,ISO)
peptidyl-tyrosine phosphorylation  (IEA,ISO,ISS)
positive regulation of angiogenesis  (IBA,IDA,IEA,ISO)
positive regulation of blood vessel endothelial cell migration  (ISO)
positive regulation of BMP signaling pathway  (IEA,ISO)
positive regulation of calcium-mediated signaling  (IMP)
positive regulation of cell migration  (IBA,IMP,ISO)
positive regulation of cell migration involved in sprouting angiogenesis  (IEA,ISO)
positive regulation of cell population proliferation  (IMP,ISO)
positive regulation of cytosolic calcium ion concentration  (IMP)
positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway  (IEA,ISO)
positive regulation of endothelial cell migration  (ISO)
positive regulation of endothelial cell proliferation  (IEA,IMP,ISO,ISS)
positive regulation of epithelial cell proliferation  (ISO)
positive regulation of ERK1 and ERK2 cascade  (IEA,ISO,ISS)
positive regulation of focal adhesion assembly  (IEA,ISO)
positive regulation of kinase activity  (IBA)
positive regulation of long-term neuronal synaptic plasticity  (IMP)
positive regulation of macroautophagy  (IEA,ISO)
positive regulation of MAPK cascade  (ISO,ISS)
positive regulation of mesenchymal cell proliferation  (IEA,ISO)
positive regulation of mitochondrial depolarization  (IEA,ISO)
positive regulation of mitochondrial fission  (IEA,ISO)
positive regulation of neurogenesis  (IEP)
positive regulation of nitric-oxide synthase biosynthetic process  (IEA,ISO,ISS)
positive regulation of phosphatidylinositol 3-kinase signaling  (IEA,IMP,ISO)
positive regulation of positive chemotaxis  (IEA,ISO)
positive regulation of protein phosphorylation  (IEA,ISO,ISS)
positive regulation of stem cell proliferation  (IEA,ISO)
positive regulation of TOR signaling  (IMP)
positive regulation of vasculogenesis  (IEA,ISO,ISS)
post-embryonic camera-type eye morphogenesis  (IEA,ISO)
protein autophosphorylation  (IDA,ISO)
protein kinase B signaling  (IEA,ISO)
regulation of bone development  (IEA,ISO)
regulation of cell shape  (IEA,ISO)
regulation of hematopoietic progenitor cell differentiation  (IEA,ISO)
regulation of MAPK cascade  (IBA)
response to axon injury  (IEP)
response to hypoxia  (IMP)
response to oxygen levels  (IEP)
response to xenobiotic stimulus  (IMP)
semaphorin-plexin signaling pathway  (IEA,ISO)
stem cell proliferation  (IEA,ISO)
surfactant homeostasis  (IEA,ISO)
transmembrane receptor protein tyrosine kinase signaling pathway  (IBA)
vascular endothelial growth factor receptor signaling pathway  (IEA,IMP,ISO,ISS)
vascular endothelial growth factor receptor-2 signaling pathway  (IEA,ISO)
vascular endothelial growth factor signaling pathway  (IEA,ISO)
vascular wound healing  (IEA,ISO)
vasculogenesis  (IEA,ISO,ISS)
vasodilation  (IGI)

Cellular Component

Phenotype Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Angelov L, etal., Cancer Res. 1999 Nov 1;59(21):5536-41.
2. Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma. Arita S, etal., Int J Gynecol Cancer. 2005 Mar-Apr;15(2):329-36.
3. Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria. Aucejo F, etal., Liver Transpl. 2009 Feb;15(2):169-76. doi: 10.1002/lt.21678.
4. Post-infarct treatment with [Pyr(1)]apelin-13 improves myocardial function by increasing neovascularization and overexpression of angiogenic growth factors in rats. Azizi Y, etal., Eur J Pharmacol. 2015 Aug 15;761:101-8. doi: 10.1016/j.ejphar.2015.04.034. Epub 2015 May 1.
5. EGFR and VEGFR2 protein expressions in bone metastases of clear cell renal cancer. Badalian G, etal., Anticancer Res. 2007 Mar-Apr;27(2):889-94.
6. [Expression of kinase insert domain-containing receptor in prostate adenocarcinoma] Bai AS, etal., Zhonghua Nan Ke Xue. 2007 Apr;13(4):324-6.
7. Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis. Beca F, etal., Mod Pathol. 2020 Aug;33(8):1518-1526. doi: 10.1038/s41379-020-0511-6. Epub 2020 Mar 2.
8. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Beebe JS, etal., Cancer Res. 2003 Nov 1;63(21):7301-9.
9. Vascular endothelial growth factor and kinase domain region receptor are involved in both seminiferous cord formation and vascular development during testis morphogenesis in the rat. Bott RC, etal., Biol Reprod. 2006 Jul;75(1):56-67. Epub 2006 May 3.
10. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Brennan M, etal., Eur J Clin Pharmacol. 2012 May;68(5):645-55. Epub 2011 Dec 15.
11. Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. Brockington A, etal., J Neuropathol Exp Neurol. 2006 Jan;65(1):26-36.
12. Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. Brown LF, etal., J Immunol. 1995 Mar 15;154(6):2801-7.
13. Combined administration of G-CSF and GM-CSF stimulates monocyte-derived pro-angiogenic cells in patients with acute myocardial infarction. Bruno S, etal., Cytokine. 2006 Apr;34(1-2):56-65. Epub 2006 May 15.
14. The VEGFR2, COX-2 and MMP-2 polymorphisms are associated with clinical outcome of patients with inoperable non-small cell lung cancer. Butkiewicz D, etal., Int J Cancer. 2015 Nov 15;137(10):2332-42. doi: 10.1002/ijc.29605. Epub 2015 Jun 3.
15. VEGF links hippocampal activity with neurogenesis, learning and memory. Cao L, etal., Nat Genet. 2004 Aug;36(8):827-35. Epub 2004 Jul 18.
16. Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis. Carrai V, etal., Rheumatology (Oxford). 2012 Jun;51(6):1042-8. doi: 10.1093/rheumatology/ker447. Epub 2012 Jan 23.
17. KDR activation in astrocytic neoplasms. Carroll RS, etal., Cancer. 1999 Oct 1;86(7):1335-41.
18. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Chae SS, etal., Clin Cancer Res. 2010 Jul 15;16(14):3618-27. Epub 2010 May 25.
19. Expression of vascular endothelial growth factor receptors in experimental otitis media in the rat. Chae SW, etal., Acta Otolaryngol. 2003 Jun;123(5):559-63.
20. The role of KDR in intrauterine adhesions may involve the TGF-β1/Smads signaling pathway. Chen JX, etal., Braz J Med Biol Res. 2019 Oct 7;52(10):e8324. doi: 10.1590/1414-431X20198324. eCollection 2019.
21. Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 following acute spinal cord contusion in rats. Choi JS, etal., J Histochem Cytochem. 2007 Aug;55(8):821-30. Epub 2007 Apr 4.
22. Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 in rat hippocampus after transient forebrain ischemia. Choi JS, etal., J Neurotrauma. 2007 Mar;24(3):521-31.
23. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Conrad C, etal., Anticancer Drugs. 2007 Jun;18(5):569-79. doi: 10.1097/CAD.0b013e3280147d13.
24. rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice. Davidoff AM, etal., Cancer Res. 2002 Jun 1;62(11):3077-83.
25. Arteriogenic erectile dysfunction alters protein expression within the cavernosal tissue in an animal model. De Young L, etal., J Sex Med. 2005 Mar;2(2):199-206.
26. [Expression of vascular endothelial growth factor receptor kinase inser domain containing receptor in human cervical carcinoma]. Di H, etal., Zhonghua Fu Chan Ke Za Zhi. 2000 Nov;35(11):670-2.
27. Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical significance. Ding M, etal., Chin J Cancer Res. 2014 Dec;26(6):669-77. doi: 10.3978/j.issn.1000-9604.2014.12.04.
28. Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer. Dong G, etal., Cancer Sci. 2012 Mar;103(3):561-8. doi: 10.1111/j.1349-7006.2011.02194.x. Epub 2012 Jan 16.
29. Peripheral blood CD34+KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. Fadini GP, etal., Stroke. 2006 Sep;37(9):2277-82. Epub 2006 Jul 27.
30. Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis. Fan L, etal., Nephron 2002 Jan;90(1):95-102.
31. Dexamethasone pre-treatment protects brain against hypoxic-ischemic injury partially through up-regulation of vascular endothelial growth factor A in neonatal rats. Feng Y, etal., Neuroscience. 2011 Apr 14;179:223-32. Epub 2011 Jan 28.
32. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Fernandez M, etal., Gastroenterology. 2004 Mar;126(3):886-94.
33. Attenuation of edema and infarct volume following focal cerebral ischemia by early but not delayed administration of a novel small molecule KDR kinase inhibitor. Foster KA, etal., Neurosci Res. 2009 Jan;63(1):10-6. Epub 2008 Oct 4.
34. Diversity of immunophenotypes of endothelial cells participating in new vessel formation following surgical rat brain injury. Frontczak-Baniewicz M, etal., J Physiol Pharmacol. 2007 Nov;58 Suppl 5(Pt 1):193-203.
35. Non-endothelial KDR/flk-1 expression is associated with increased survival of patients with urothelial bladder carcinomas. Gakiopoulou-Givalou H, etal., Histopathology. 2003 Sep;43(3):272-9.
36. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
37. Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. Gebhardt M, etal., Ophthalmology. 2005 Jun;112(6):1023-30.
38. The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Giatromanolaki A, etal., Cancer. 2001 Nov 15;92(10):2569-77.
39. Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2alpha and survival. Giatromanolaki A, etal., Clin Exp Metastasis. 2012 Jan;29(1):11-7. doi: 10.1007/s10585-011-9424-6. Epub 2011 Oct 9.
40. Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis. Giatromanolaki A, etal., Mod Pathol. 2006 May;19(5):701-7.
41. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
42. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Gomez R, etal., Endocrinology 2002 Nov;143(11):4339-48.
43. Overexpression of vascular endothelial growth factor receptor 2 in pterygia may have a predictive value for a higher postoperative recurrence rate. Gumus K, etal., Br J Ophthalmol. 2013 Feb 1.
44. [The significance and expression of vascular endothelial growth factor on nasal inverted papillomas]. Han FJ, etal., Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2000 Feb;14(2):65-7.
45. Minor salivary gland carcinoma: a review of 35 cases. Haymerle G, etal., Eur Arch Otorhinolaryngol. 2016 Sep;273(9):2717-26. doi: 10.1007/s00405-015-3805-4. Epub 2015 Oct 23.
46. Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation. Heffelfinger SC, etal., Lab Invest. 2004 Aug;84(8):989-98.
47. Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis. Henno A, etal., J Dermatol Sci. 2010 Mar;57(3):162-9. doi: 10.1016/j.jdermsci.2009.12.006. Epub 2010 Jan 7.
48. Polymorphisms in Vascular Endothelial Growth Factor Receptor 2 Are Associated with Better Response Rates to Ranibizumab Treatment in Age-related Macular Degeneration. Hermann MM, etal., Ophthalmology. 2013 Dec 20. pii: S0161-6420(13)01056-7. doi: 10.1016/j.ophtha.2013.10.047.
49. Expression pattern of VEGFR-1, -2, -3 and D2-40 protein in the skin of patients with systemic sclerosis. Higashi-Kuwata N, etal., Eur J Dermatol. 2011 Jul-Aug;21(4):490-4. doi: 10.1684/ejd.2011.1284.
50. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Holmes K, etal., Cell Signal. 2007 Oct;19(10):2003-12. Epub 2007 Jun 12.
51. Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye. Huang H, etal., PLoS One. 2011;6(6):e21411. Epub 2011 Jun 22.
52. Dietary alpha-linolenic acid-rich formula reduces adhesion molecules in rats with experimental colitis. Ibrahim A, etal., Nutrition. 2012 Jul;28(7-8):799-802. doi: 10.1016/j.nut.2011.10.008. Epub 2012 Jan 20.
53. Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors. Inan S, etal., Histol Histopathol. 2006 Oct;21(10):1055-64.
54. Differential gene expression of vascular endothelial growth factor isoforms and their receptors in the development of the rat masseter muscle. Ishii H, etal., Arch Oral Biol 2002 Jul;47(7):505-10.
55. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. Jain L, etal., J Exp Clin Cancer Res. 2010 Jul 14;29:95. doi: 10.1186/1756-9966-29-95.
56. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Jantus-Lewintre E, etal., Lung Cancer. 2011 Nov;74(2):326-31. doi: 10.1016/j.lungcan.2011.02.016. Epub 2011 Apr 9.
57. Differential effects of selective endothelin type a receptor antagonist on the gene expression of vascular endothelial growth factor and its receptors in streptozotocin-induced diabetic heart. Jesmin S, etal., Exp Biol Med (Maywood). 2006 Jun;231(6):902-6.
58. Time-Dependent Alterations of VEGF and Its Signaling Molecules in Acute Lung Injury in a Rat Model of Sepsis. Jesmin S, etal., Inflammation. 2011 Apr 29.
59. Brain expression of VEGF and its receptors in SHR-SP and effects of an endothelin blocker. Jesmin S, etal., J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S160-4.
60. Vascular endothelial growth factor stimulates neurite outgrowth from cerebral cortical neurons via Rho kinase signaling. Jin K, etal., J Neurobiol. 2006 Feb 15;66(3):236-42.
61. Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis. Jinnin M, etal., Br J Dermatol. 2010 Apr;162(4):751-8. doi: 10.1111/j.1365-2133.2009.09567.x. Epub 2009 Nov 3.
62. Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice. Karashima T, etal., Int J Oncol. 2007 Apr;30(4):937-45.
63. Expression of vascular endothelial growth factor in eyes with Coats' disease. Kase S, etal., Invest Ophthalmol Vis Sci. 2013 Jan 7;54(1):57-62. doi: 10.1167/iovs.12-10613.
64. Receptor protein tyrosine kinases in perinatal developing rat kidney. Kee N, etal., Kidney Int. 1997 Aug;52(2):309-17.
65. DCE-MRI in Glioma, Infiltration Zone and Healthy Brain to Assess Angiogenesis: A Biopsy Study. Keil VC, etal., Clin Neuroradiol. 2021 Dec;31(4):1049-1058. doi: 10.1007/s00062-021-01015-3. Epub 2021 Apr 26.
66. Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization. Keskin U, etal., Ophthalmic Res. 2012;47(1):13-8. doi: 10.1159/000324994. Epub 2011 Jun 21.
67. Vascular endothelial growth factor receptor 2-based DNA immunization delays development of herpetic stromal keratitis by antiangiogenic effects. Kim B, etal., J Immunol. 2006 Sep 15;177(6):4122-31.
68. Vascular endothelial growth factor (VEGF) signaling regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium/calmodulin protein kinase II and mammalian target of rapamycin. Kim BW, etal., Cell Signal. 2008 Apr;20(4):714-25. Epub 2007 Dec 17.
69. Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis. Kim DG, etal., MAbs. 2015;7(6):1195-204. doi: 10.1080/19420862.2015.1086854. Epub 2015 Sep 1.
70. Distinct roles of vascular endothelial growth factor receptor-1- and receptor-2-mediated signaling in T cell priming and Th17 polarization to lipopolysaccharide-containing allergens in the lung. Kim YS, etal., J Immunol. 2010 Nov 1;185(9):5648-55. Epub 2010 Oct 4.
71. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. Kinose F, etal., Mol Vis. 2005 May 27;11:366-73.
72. Effects of experimental type 1 diabetes and exercise training on angiogenic gene expression and capillarization in skeletal muscle. Kivela R, etal., FASEB J. 2006 Jul;20(9):1570-2.
73. Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Kranenburg AR, etal., Thorax. 2005 Feb;60(2):106-13.
74. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Kranz A, etal., Int J Cancer. 1999 Jun 21;84(3):293-8.
75. Neurovascular factors in wound healing in the foot skin of type 2 diabetic subjects. Krishnan ST, etal., Diabetes Care. 2007 Dec;30(12):3058-62. Epub 2007 Sep 26.
76. Angiogenic and astroglial responses to vascular endothelial growth factor administration in adult rat brain. Krum JM, etal., Neuroscience. 2002;110(4):589-604.
77. Hind-limb paraparesis in a rat model for neurolathyrism associated with apoptosis and an impaired vascular endothelial growth factor system in the spinal cord. Kusama-Eguchi K, etal., J Comp Neurol. 2010 Mar 15;518(6):928-42.
78. The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. Lazzeri S, etal., ScientificWorldJournal. 2012;2012:420190. doi: 10.1100/2012/420190. Epub 2012 Aug 1.
79. Inhibition of VEGF receptor 2 increased cell death of dentate hilar neurons after traumatic brain injury. Lee C and Agoston DV, Exp Neurol. 2009 Dec;220(2):400-3. Epub 2009 Sep 3.
80. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis. Lee WS, etal., MAbs. 2015;7(5):957-68. doi: 10.1080/19420862.2015.1045168. Epub 2015 May 5.
81. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Li B, etal., Hypertension. 2002 Jun;39(6):1095-100.
82. VEGF and its receptor-2 involved in neuropathic pain transmission mediated by P2X(/) receptor of primary sensory neurons. Lin J, etal., Brain Res Bull. 2010 Oct 30;83(5):284-91. Epub 2010 Aug 10.
83. Inverse correlation of phospho-KDR/Flk-1 expression and stage of colorectal cancer: implication of the significance of neoangiogenesis in activated VEGFR-2 expressing early stage colorectal adenocarcinomas. Lin YF, etal., Pol J Pathol. 2014 Oct;65(3):194-201. doi: 10.5114/pjp.2014.45781.
84. Multiple receptor tyrosine kinases are expressed in adult rat retinal ganglion cells as revealed by single-cell degenerate primer polymerase chain reaction. Lindqvist N, etal., Ups J Med Sci. 2010 Feb;115(1):65-80. doi: 10.3109/03009731003597119.
85. Hyaluronan mixed esters of butyric and retinoic acid affording myocardial survival and repair without stem cell transplantation. Lionetti V, etal., J Biol Chem. 2010 Mar 26;285(13):9949-61. doi: 10.1074/jbc.M109.087254. Epub 2010 Jan 22.
86. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder. Liu L, etal., Urol Int. 2008;81(1):72-6. Epub 2008 Jul 16.
87. [Pathogenesis of retinal neovascularization in a rat model of oxygen fluctuations-induced retinopathy]. Liu X, etal., Zhonghua Er Ke Za Zhi. 2007 Jan;45(1):7-13.
88. Ponicidin induces apoptosis via JAK2 and STAT3 signaling pathways in gastric carcinoma. Liu YF, etal., Int J Mol Sci. 2015 Jan 12;16(1):1576-89. doi: 10.3390/ijms16011576.
89. In vivo imaging and characterization of hypoxia-induced neovascularization and tumor invasion. Lungu GF, etal., Int J Oncol. 2007 Jan;30(1):45-54.
90. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model. Machado DE, etal., Fertil Steril. 2010 May 15;93(8):2674-9. Epub 2010 Jan 13.
91. Genetic polymorphisms of proangiogenic factors seem to favor hepatocellular carcinoma development in alcoholic cirrhosis. Machado MV, etal., Eur J Gastroenterol Hepatol. 2014 Apr;26(4):438-43. doi: 10.1097/MEG.0000000000000044.
92. Cigarette smoke disrupts VEGF165-VEGFR-2 receptor signaling complex in rat lungs and patients with COPD: morphological impact of VEGFR-2 inhibition. Marwick JA, etal., Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L897-908. Epub 2005 Dec 16.
93. [Prognostic significance of serum level of vascular endothelial growth factor receptor-2 in hepatocellular carcinoma patients after transcatheter arterial chemoembolization]. Meng QW, etal., Zhonghua Yi Xue Za Zhi. 2013 Jan 29;93(5):341-4.
94. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Meunier-Carpentier S, etal., Int J Oncol. 2005 Apr;26(4):977-84.
95. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
96. Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. Miller DW, etal., Am J Pathol. 2005 Nov;167(5):1389-403.
97. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Miyazawa M, etal., Cancer Sci. 2010 Feb;101(2):433-9. Epub 2009 Oct 27.
98. Suppression of alkali burn-induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2. Mochimaru H, etal., Invest Ophthalmol Vis Sci. 2008 May;49(5):2172-7. doi: 10.1167/iovs.07-1396. Epub 2008 Feb 8.
99. KLF5/BTEB2, a Kruppel-like zinc-finger type transcription factor, mediates both smooth muscle cell activation and cardiac hypertrophy. Nagai R, etal., Adv Exp Med Biol 2003;538:57-65; discussion 66.
100. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Nakopoulou L, etal., Hum Pathol. 2002 Sep;33(9):863-70.
101. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
102. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Niethammer AG, etal., Nat Med. 2002 Dec;8(12):1369-75. doi: 10.1038/nm1202-794. Epub 2002 Nov 4.
103. Association of inflammatory factors with macular edema in branch retinal vein occlusion. Noma H, etal., JAMA Ophthalmol. 2013 Feb;131(2):160-5. doi: 10.1001/2013.jamaophthalmol.228.
104. Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas. Norgall S, etal., BMC Cancer. 2007 Jun 21;7:105.
105. Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation. Nykanen AI, etal., Transplantation. 2005 Jan 27;79(2):182-9.
106. VEGF receptor signalling - in control of vascular function. Olsson AK, etal., Nat Rev Mol Cell Biol. 2006 May;7(5):359-71.
107. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
108. Heparin affin regulatory peptide/pleiotrophin negatively affects diverse biological activities in C6 glioma cells. Parthymou A, etal., Eur J Cell Biol. 2008 Jan;87(1):17-29. Epub 2007 Sep 18.
109. Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain. Peoch M, etal., Anticancer Res 2002 Jul-Aug;22(4):2147-51.
110. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Petrovan RJ, etal., Arterioscler Thromb Vasc Biol. 2007 May;27(5):1095-100. Epub 2007 Feb 15.
111. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Pieh C, etal., Br J Ophthalmol. 2008 May;92(5):689-93. doi: 10.1136/bjo.2007.128371. Epub 2008 Apr 11.
112. Activation of multiple angiogenic signaling pathways in hemangiopericytoma. Pierscianek D, etal., Brain Tumor Pathol. 2016 Jul;33(3):200-8. doi: 10.1007/s10014-016-0256-6. Epub 2016 Mar 7.
113. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
114. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
115. SMPDB Annotation Import Pipeline Pipeline to import SMPDB annotations from SMPDB into RGD
116. VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas. Pisacane AM and Risio M, Melanoma Res. 2005 Feb;15(1):39-43.
117. The angiogenic peptide vascular endothelial growth factor (VEGF) is expressed in chronic sacral pressure ulcers. Pufe T, etal., J Pathol. 2003 May;200(1):130-6.
118. Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. Ran S, etal., Neoplasia. 2003 Jul-Aug;5(4):297-307.
119. Soluble Vascular Endothelial Growth Factor Receptor-2 as a Predictive Factor for Progression of Illness in Chronic Liver Diseases and Hepatocellular Carcinoma. Ratnasari N, etal., Kobe J Med Sci. 2015 Dec 18;61(3):E89-96.
120. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Renno RZ, etal., Arch Ophthalmol. 2004 Jul;122(7):1002-11.
121. GOA pipeline RGD automated data pipeline
122. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
123. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
124. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. Roland CL, etal., PLoS One. 2009 Nov 3;4(11):e7669.
125. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE. Roscoe WA, etal., J Neuroimmunol. 2009 Apr 30;209(1-2):6-15. Epub 2009 Feb 23.
126. The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue. Sano D, etal., Arch Otolaryngol Head Neck Surg. 2009 Apr;135(4):411-20. doi: 10.1001/archoto.2009.14.
127. Flt1 and Flk1 mediate regulation of intraocular pressure and their double heterozygosity causes the buphthalmia in mice. Sano K, etal., Biochem Biophys Res Commun. 2012 Apr 6;420(2):422-7. doi: 10.1016/j.bbrc.2012.03.011. Epub 2012 Mar 9.
128. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. Sasso FC, etal., J Am Coll Cardiol. 2005 Sep 6;46(5):827-34.
129. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Scaldaferri F, etal., Gastroenterology. 2009 Feb;136(2):585-95.e5. Epub 2008 Oct 7.
130. Astrocyte responses to injury: VEGF simultaneously modulates cell death and proliferation. Schmid-Brunclik N, etal., Am J Physiol Regul Integr Comp Physiol. 2008 Sep;295(3):R864-73. Epub 2008 Jul 9.
131. Local VEGF inhibition prevents ovarian alterations associated with ovarian hyperstimulation syndrome. Scotti L, etal., J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:392-401. doi: 10.1016/j.jsbmb.2014.08.013. Epub 2014 Aug 23.
132. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Seto T, etal., Lung Cancer. 2006 Jul;53(1):91-6. doi: 10.1016/j.lungcan.2006.02.009. Epub 2006 May 11.
133. [Expression and clinical significance of VEGF and its receptors Flt-1 and KDR in nasopharyngeal carcinoma]. Sha D and He YJ, Ai Zheng. 2006 Feb;25(2):229-34.
134. Zhonghua nan ke xue = National journal of andrology Shao JC, etal., Zhonghua Nan Ke Xue. 2005 Jun;11(6):413-8.
135. Vascular endothelial growth factor receptor-2 inhibition promotes cell death and limits endothelial cell proliferation in a neonatal rodent model of stroke. Shimotake J, etal., Stroke. 2010 Feb;41(2):343-9.
136. Reduction of a vascular endothelial growth factor receptor, fetal liver kinase-1, by antisense oligonucleotides induces motor neuron death in rat spinal cord exposed to hypoxia. Shiote M, etal., Neuroscience. 2005;132(1):175-82.
137. Nine Genes Mediate the Therapeutic Effects of Iodine-131 Radiotherapy in Thyroid Carcinoma Patients. Shuwen H, etal., Dis Markers. 2020 Jun 16;2020:9369341. doi: 10.1155/2020/9369341. eCollection 2020.
138. VEGF and VEGF receptor expression after experimental brain contusion in rat. Skold MK, etal., J Neurotrauma. 2005 Mar;22(3):353-67.
139. Vascular therapy for radiation cystitis. Soler R, etal., Neurourol Urodyn. 2011 Mar;30(3):428-34. doi: 10.1002/nau.21002. Epub 2010 Oct 29.
140. Normal aging involves altered expression of growth factors in the rat choroid. Steinle JJ, etal., J Gerontol A Biol Sci Med Sci. 2008 Feb;63(2):135-40.
141. Gamma-Secretase Inhibitor, DAPT, Prevents the Development of Retinopathy of Prematurity in a Rat Model by Regulating the Delta-Like Ligand 4/Notch Homolog-1 (DLL4/Notch-1) Pathway. Sun W, etal., Med Sci Monit. 2019 Jan 17;25:492-499. doi: 10.12659/MSM.913828.
142. Identification of a novel vascular endothelial growth factor receptor 2 inhibitor and its effect for choroidal neovascularization in vivo. Takahashi H, etal., Curr Eye Res. 2008 Nov;33(11):1002-10. doi: 10.1080/02713680802492440.
143. Suppression of choroidal neovascularization by vaccination with epitope peptide derived from human VEGF receptor 2 in an animal model. Takahashi H, etal., Invest Ophthalmol Vis Sci. 2008 May;49(5):2143-7. doi: 10.1167/iovs.07-0523.
144. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Takahashi T and Shibuya M, Oncogene. 1997 May 1;14(17):2079-89.
145. Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor. Takeda A, etal., Graefes Arch Clin Exp Ophthalmol. 2003 Sep;241(9):765-72. Epub 2003 Aug 23.
146. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Tardy I, etal., Invest Radiol. 2010 Oct;45(10):573-8.
147. Tentative Sequence Identification Numbers Tentative Sequence Data IDs. TIGR Gene Index, Rat Data
148. Dual suppression of hemangiogenesis and lymphangiogenesis by splice-shifting morpholinos targeting vascular endothelial growth factor receptor 2 (KDR). Uehara H, etal., FASEB J. 2013 Jan;27(1):76-85. doi: 10.1096/fj.12-213835. Epub 2012 Sep 20.
149. Expression of VEGF and its receptor genes in intracranial schwannomas. Uesaka T, etal., J Neurooncol. 2007 Jul;83(3):259-66. Epub 2007 Feb 14.
150. Expression of endothelial cell angiogenesis receptors in human cerebrovascular malformations. Uranishi R, etal., Neurosurgery. 2001 Feb;48(2):359-67; discussion 367-8.
151. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. Vajkoczy P, etal., J Clin Invest 2002 Mar;109(6):777-85.
152. Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab. Vihinen PP, etal., Melanoma Res. 2011 Oct;21(5):431-7. doi: 10.1097/CMR.0b013e32834941d3.
153. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. Waldner MJ, etal., J Exp Med. 2010 Dec 20;207(13):2855-68. Epub 2010 Nov 22.
154. Zhonghua bing li xue za zhi Chinese journal of pathology Wang H, etal., Zhonghua Bing Li Xue Za Zhi. 2002 Oct;31(5):391-5.
155. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Warner-Schmidt JL and Duman RS, Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4647-52. Epub 2007 Mar 5.
156. Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity. Watanabe H, etal., Exp Dermatol. 2004 Nov;13(11):671-81.
157. Lipocortin V may function as a signaling protein for vascular endothelial growth factor receptor-2/Flk-1. Wen Y, etal., Biochem Biophys Res Commun. 1999 May 19;258(3):713-21.
158. Two functional forms of vascular endothelial growth factor receptor-2/Flk-1 mRNA are expressed in normal rat retina. Wen Y, etal., J Biol Chem 1998 Jan 23;273(4):2090-7.
159. Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Wilkinson-Berka JL, etal., Am J Pathol. 2004 Apr;164(4):1263-73.
160. Induction of angiogenesis and modulation of vascular endothelial growth factor receptor-2 by simvastatin after traumatic brain injury. Wu H, etal., Neurosurgery. 2011 May;68(5):1363-71; discussion 1371.
161. Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma. Wu IC, etal., Neoplasia. 2011 Apr;13(4):386-92. doi: 10.1593/neo.101722.
162. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. Xia G, etal., J Urol. 2006 Apr;175(4):1245-52.
163. A new selective vascular endothelial growth factor receptor 2 inhibitor ablates disease in a mouse model of psoriasis. Yan HX, etal., Mol Med Rep. 2013 Aug;8(2):434-8. doi: 10.3892/mmr.2013.1500. Epub 2013 May 31.
164. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Yang F, etal., Cancer Res. 2011 Aug 15;71(16):5512-21. doi: 10.1158/0008-5472.CAN-10-2614. Epub 2011 Jul 1.
165. Expression and significance of the vascular permeability factor in nasal polyps. Yang J, etal., Chin Med J (Engl). 2002 Aug;115(8):1251-2.
166. Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors. Yazawa H, etal., Cancer Gene Ther. 2006 Nov;13(11):993-1001. doi: 10.1038/sj.cgt.7700970. Epub 2006 Jun 9.
167. Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma. Yockman JW, etal., Gene Ther. 2007 Oct;14(19):1399-405. Epub 2007 Jul 26.
168. Increased expression of tissue vascular endothelial growth factor and foetal liver kinase-1 receptor in seasonal allergic rhinitis and relevance to asthma component. Yuksel H, etal., Clin Exp Allergy. 2007 Aug;37(8):1183-8.
169. Two isoforms of flk-1 transcripts in early diabetic rat retinas. Zhang X, etal., Curr Eye Res. 2012 Jan;37(1):73-9. Epub 2011 Nov 28.
170. Extracellular domain of kinase domain region mediated by adeno-associated virus inhibits growth and angiogenesis of bladder cancer in Balb-c mice. Zhang Z, etal., Chin Med J (Engl). 2002 Aug;115(8):1209-12.
171. The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib. Zheng YB, etal., Med Oncol. 2014 Oct;31(10):209. doi: 10.1007/s12032-014-0209-z. Epub 2014 Sep 3.
172. The VEGFR-2 protein and the VEGFR-2 rs1870377 A>T genetic polymorphism are prognostic factors for gastric cancer. Zhu X, etal., Cancer Biol Ther. 2019;20(4):497-504. doi: 10.1080/15384047.2018.1537575. Epub 2018 Oct 31.
173. Peritumoral Neuropilin-1 and VEGF receptor-2 expression increases time to recurrence in hepatocellular carcinoma patients undergoing curative hepatectomy. Zhuang PY, etal., Oncotarget. 2014 Nov 30;5(22):11121-32. doi: 10.18632/oncotarget.2553.
174. Orally administered DNA vaccine delivery by attenuated Salmonella typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis. Zuo SG, etal., Biol Pharm Bull. 2010;33(2):174-82. doi: 10.1248/bpb.33.174.
Additional References at PubMed
PMID:1323289   PMID:1417831   PMID:7596435   PMID:7681362   PMID:7929439   PMID:7999104   PMID:8356051   PMID:9398617   PMID:9804796   PMID:9837777   PMID:10022831   PMID:10037737  
PMID:10102632   PMID:10600473   PMID:10705382   PMID:10878616   PMID:11387210   PMID:11950700   PMID:11967019   PMID:12053176   PMID:12477932   PMID:12569129   PMID:12631117   PMID:12753865  
PMID:12820653   PMID:12897140   PMID:12923895   PMID:14766216   PMID:15215251   PMID:15548727   PMID:15601856   PMID:15644447   PMID:15734877   PMID:15919309   PMID:15962004   PMID:16010973  
PMID:16099728   PMID:16375885   PMID:16455951   PMID:16901919   PMID:16944045   PMID:17050862   PMID:17293873   PMID:17418870   PMID:17651752   PMID:17854994   PMID:17889862   PMID:18174522  
PMID:18321563   PMID:18421240   PMID:18462699   PMID:18482723   PMID:18586890   PMID:18772315   PMID:18835919   PMID:18977327   PMID:19033661   PMID:19357264   PMID:19426150   PMID:19513111  
PMID:19575935   PMID:19635461   PMID:19774558   PMID:20080685   PMID:20103598   PMID:20116868   PMID:20228271   PMID:20406889   PMID:20439428   PMID:20497492   PMID:20550877   PMID:20572782  
PMID:20599605   PMID:20637183   PMID:20660291   PMID:20697002   PMID:21418372   PMID:21435466   PMID:21613481   PMID:21885851   PMID:21928073   PMID:22245234   PMID:22265737   PMID:22499991  
PMID:22569153   PMID:22886301   PMID:22949406   PMID:23262137   PMID:23348691   PMID:23456363   PMID:23529610   PMID:23639442   PMID:23684887   PMID:23688497   PMID:23732519   PMID:23798385  
PMID:23826635   PMID:23831211   PMID:24022223   PMID:24063000   PMID:24205206   PMID:24398936   PMID:24623966   PMID:24630601   PMID:24863063   PMID:25195697   PMID:25730004   PMID:25754303  
PMID:25893857   PMID:26509169   PMID:26879375   PMID:27439004   PMID:27733124   PMID:28457321   PMID:28637396   PMID:28958753   PMID:29710417   PMID:30816491   PMID:30873824   PMID:31406128  
PMID:31583245   PMID:32189115   PMID:32481647   PMID:32918705   PMID:33008083   PMID:33671638   PMID:33904385   PMID:34169992  


Genomics

Comparative Map Data
Kdr
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.21432,217,871 - 32,261,018 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1432,217,871 - 32,261,018 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1432,577,934 - 32,621,098 (+)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.01433,885,873 - 33,929,041 (+)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.01432,370,973 - 32,414,143 (+)NCBIRnor_WKY
Rnor_6.01434,727,677 - 34,787,127 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1434,727,623 - 34,787,183 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01434,557,361 - 34,618,112 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera1431,512,534 - 31,554,989 (+)NCBICelera
Cytogenetic Map14p11NCBI
KDR
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh38455,078,481 - 55,125,595 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 Ensembl455,078,481 - 55,125,595 (-)EnsemblGRCh38hg38GRCh38
GRCh37455,944,648 - 55,991,762 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 36455,639,406 - 55,686,519 (-)NCBINCBI36Build 36hg18NCBI36
Build 34455,785,576 - 55,832,690NCBI
Celera453,446,341 - 53,493,673 (-)NCBICelera
Cytogenetic Map4q12NCBI
HuRef451,893,013 - 51,940,346 (-)NCBIHuRef
CHM1_1455,979,683 - 56,027,015 (-)NCBICHM1_1
T2T-CHM13v2.0458,566,962 - 58,614,067 (-)NCBIT2T-CHM13v2.0
Kdr
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm39576,093,487 - 76,139,885 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl576,093,487 - 76,139,118 (-)EnsemblGRCm39 Ensembl
GRCm38575,932,827 - 75,979,072 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl575,932,827 - 75,978,458 (-)EnsemblGRCm38mm10GRCm38
MGSCv37576,329,290 - 76,374,453 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36576,214,962 - 76,260,125 (-)NCBIMGSCv36mm8
Celera573,218,468 - 73,263,674 (-)NCBICelera
Cytogenetic Map5C3.3NCBI
cM Map540.23NCBI
Kdr
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_00495544715,810,815 - 15,853,583 (+)EnsemblChiLan1.0
ChiLan1.0NW_00495544715,810,816 - 15,851,702 (+)NCBIChiLan1.0ChiLan1.0
KDR
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
PanPan1.1475,377,847 - 75,424,927 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl475,377,375 - 75,427,109 (+)Ensemblpanpan1.1panPan2
Mhudiblu_PPA_v0468,813,894 - 68,861,018 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
KDR
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.11347,442,861 - 47,484,574 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1347,442,764 - 47,485,042 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1347,400,610 - 47,442,293 (-)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01348,053,730 - 48,095,387 (-)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1348,053,595 - 48,095,437 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11347,729,487 - 47,771,112 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01347,258,117 - 47,299,735 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01348,206,381 - 48,248,022 (-)NCBIUU_Cfam_GSD_1.0
Kdr
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_02440528528,716,920 - 28,760,830 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_00493648217,538,864 - 17,581,002 (-)EnsemblSpeTri2.0
SpeTri2.0NW_00493648217,537,697 - 17,581,320 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
KDR
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl841,809,122 - 41,856,336 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.1841,809,116 - 41,856,379 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2843,919,330 - 43,966,984 (-)NCBISscrofa10.2Sscrofa10.2susScr3
KDR
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.1713,435,059 - 13,482,236 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl713,435,096 - 13,482,771 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366606614,207,326 - 14,254,753 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Kdr
(Heterocephalus glaber - naked mole-rat)
Naked Mole-rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_00462476114,330,489 - 14,379,051 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_00462476114,330,224 - 14,380,680 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Kdr
162 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:764
Count of miRNA genes:299
Interacting mature miRNAs:387
Transcripts:ENSRNOT00000071405
Prediction methods:Microtar, Miranda, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
619619Rf4Renal disease susceptibility QTL 44.10.002urine total protein amount (VT:0000032)urine protein excretion rate to body weight ratio (CMO:0001099)14132754612Rat
634352Apr6Acute phase response QTL 63.7blood interleukin-6 amount (VT:0008595)plasma interleukin-6 level (CMO:0001927)14141131407Rat
1581500Renag1Renal agenesis QTL 1kidney development trait (VT:0000527)percentage of study population developing unilateral renal agenesis during a period of time (CMO:0000940)14817066868298175Rat
1358296Ael3Aortic elastin QTL 33.70.00051aorta elastin amount (VT:0003905)aortic elastin14826709053267090Rat
2302045Pia39Pristane induced arthritis QTL 394.90.001blood immunoglobulin amount (VT:0002460)serum immunoglobulin G2a level (CMO:0002116)14826709053267090Rat
731183Pia20Pristane induced arthritis QTL 203.55joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)14908897839057237Rat
631839Niddm37Non-insulin dependent diabetes mellitus QTL 373.37blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)141103062295876975Rat
71117Niddm17Non-insulin dependent diabetes mellitus QTL 172.35blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)141759376142336881Rat
631262Tcas4Tongue tumor susceptibility QTL 47.29tongue integrity trait (VT:0010553)number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950)141762256142337007Rat
2313397Coatc1Coat color QTL1coat/hair pigmentation trait (VT:0010463)coat/hair color measurement (CMO:0001808)141854133263541332Rat
61420Pia6Pristane induced arthritis QTL 64.9joint integrity trait (VT:0010548)arthritic paw count (CMO:0001460)141863134542337007Rat
10755459Coatc15Coat color QTL 150.01681coat/hair pigmentation trait (VT:0010463)pigmented ventral coat/hair area to total ventral coat/hair area ratio (CMO:0001812)141983694464836944Rat
70187Pancm5Pancreatic morphology QTL 516.7pancreas mass (VT:0010144)pancreas weight to body weight ratio (CMO:0000630)143032009280829842Rat
2324617Coatc2Coat color QTL 20.001coat/hair pigmentation trait (VT:0010463)pigmented coat/hair area to total coat/hair area ratio (CMO:0001810)143076702539153750Rat
1300154Bp189Blood pressure QTL 1893.04arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)143088377768757901Rat

Markers in Region
RH128586  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21432,260,625 - 32,260,844 (+)MAPPERmRatBN7.2
Rnor_6.01434,786,739 - 34,786,957NCBIRnor6.0
Rnor_5.01434,617,724 - 34,617,942UniSTSRnor5.0
Celera1431,554,601 - 31,554,819UniSTS
RH 3.4 Map14431.29UniSTS
RH94641  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21432,260,812 - 32,260,983 (+)MAPPERmRatBN7.2
Rnor_6.01434,786,926 - 34,787,096NCBIRnor6.0
Rnor_5.01434,617,911 - 34,618,081UniSTSRnor5.0
Celera1431,554,788 - 31,554,958UniSTS
AU048544  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21432,234,079 - 32,234,343 (+)MAPPERmRatBN7.2
Rnor_6.01434,743,872 - 34,744,135NCBIRnor6.0
Rnor_5.01434,573,535 - 34,573,798UniSTSRnor5.0
Celera1431,528,517 - 31,528,780UniSTS


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 43 41 31 13 31 4 4 55 35 30 11 4
Low 3 16 10 6 10 4 7 19 10 4
Below cutoff 1

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000071405   ⟹   ENSRNOP00000066886
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1432,217,871 - 32,261,018 (+)Ensembl
Rnor_6.0 Ensembl1434,727,623 - 34,787,183 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000085089   ⟹   ENSRNOP00000071349
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1432,222,596 - 32,261,018 (+)Ensembl
Rnor_6.0 Ensembl1434,727,915 - 34,785,518 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000090183   ⟹   ENSRNOP00000069697
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl1434,727,677 - 34,787,124 (+)Ensembl
RefSeq Acc Id: NM_013062   ⟹   NP_037194
RefSeq Status: VALIDATED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.21432,217,871 - 32,261,018 (+)NCBI
Rnor_6.01434,727,677 - 34,787,127 (+)NCBI
Rnor_5.01434,557,361 - 34,618,112 (+)NCBI
Celera1431,512,534 - 31,554,989 (+)RGD
Sequence:
Reference Sequences
RefSeq Acc Id: NP_037194   ⟸   NM_013062
- Peptide Label: precursor
- UniProtKB: M0RBF2 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000069697   ⟸   ENSRNOT00000090183
RefSeq Acc Id: ENSRNOP00000071349   ⟸   ENSRNOT00000085089
RefSeq Acc Id: ENSRNOP00000066886   ⟸   ENSRNOT00000071405
Protein Domains
Ig-like   Ig-like C2-type   Protein kinase

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-O08775-F1-model_v2 AlphaFold O08775 1-1343 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13699278
Promoter ID:EPDNEW_R9803
Type:single initiation site
Name:Kdr_1
Description:kinase insert domain receptor
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Alternative Promoters:null; see alsoEPDNEW_R9804  
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.01434,727,648 - 34,727,708EPDNEW
RGD ID:13699284
Promoter ID:EPDNEW_R9804
Type:single initiation site
Name:Kdr_2
Description:kinase insert domain receptor
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Alternative Promoters:null; see alsoEPDNEW_R9803  
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.01434,727,925 - 34,727,985EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2965 AgrOrtholog
BioCyc Gene G2FUF-15933 BioCyc
Ensembl Genes ENSRNOG00000046829 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000066886 ENTREZGENE
  ENSRNOP00000066886.2 UniProtKB/TrEMBL
  ENSRNOP00000071349.2 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000071405 ENTREZGENE
  ENSRNOT00000071405.3 UniProtKB/TrEMBL
  ENSRNOT00000085089.2 UniProtKB/TrEMBL
Gene3D-CATH 2.60.40.10 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
IMAGE_CLONE IMAGE:7124961 IMAGE-MGC_LOAD
InterPro Ig-like_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig-like_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig-like_fold UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig_I-set UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig_sub UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig_sub2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Immunoglobulin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kinase-like_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Prot_kinase_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Protein_kinase_ATP_BS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ser-Thr/Tyr_kinase_cat_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_AS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_cat_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_rcpt_3_CS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  VEGFR-2_TMD UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  VEGFR2_rcpt UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:25589 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
MGC_CLONE MGC:93590 IMAGE-MGC_LOAD
NCBI Gene 25589 ENTREZGENE
Pfam I-set UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PF00047 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Pkinase_Tyr UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  VEGFR-2_TMD UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PharmGKB KDR RGD
PhenoGen Kdr PhenoGen
PRINTS VEGFRECEPTR2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PROSITE IG_LIKE UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PROTEIN_KINASE_ATP UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PROTEIN_KINASE_DOM UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PROTEIN_KINASE_TYR UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  RECEPTOR_TYR_KIN_III UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
SMART IGc2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SM00409 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TyrKc UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF48726 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF56112 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
TIGR TC230153
UniProt A0A0G2K090_RAT UniProtKB/TrEMBL
  M0RBF2 ENTREZGENE
  O08775 ENTREZGENE
  Q5PQU0_RAT UniProtKB/TrEMBL
  VGFR2_RAT UniProtKB/Swiss-Prot
UniProt Secondary M0RBF2 UniProtKB/TrEMBL


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2009-12-15 Kdr  kinase insert domain receptor  Kdr  kinase insert domain protein receptor  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2002-11-06 Kdr  kinase insert domain protein receptor    FLK1 kinase insert domain receptor (VEGF receptor 2)  Name updated 625702 APPROVED
2002-06-10 Kdr  FLK1 kinase insert domain receptor (VEGF receptor 2)      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_expression expressed in retina 729081
gene_process mediates initiation of vascular growth by angiogenic sprouting; plays a role in endothelial cell proliferation, differentiation, and microvascular permeability 625690
gene_process activation induces vascular permeability 729115